BR112019013593A2 - Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase - Google Patents
Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase Download PDFInfo
- Publication number
- BR112019013593A2 BR112019013593A2 BR112019013593-6A BR112019013593A BR112019013593A2 BR 112019013593 A2 BR112019013593 A2 BR 112019013593A2 BR 112019013593 A BR112019013593 A BR 112019013593A BR 112019013593 A2 BR112019013593 A2 BR 112019013593A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- chloroisoquinolin
- alkyl
- picolinamide
- group
- Prior art date
Links
- 0 Cc1cncc(*)c1 Chemical compound Cc1cncc(*)c1 0.000 description 4
- DSCVAFLYRUEBNJ-UHFFFAOYSA-N CCC(c1ccccn1)N1CCOCC1 Chemical compound CCC(c1ccccn1)N1CCOCC1 DSCVAFLYRUEBNJ-UHFFFAOYSA-N 0.000 description 1
- NINDRFYNLDAFAD-UHFFFAOYSA-N COC(c(nc1)ccc1Nc1nccc2c1cccc2Cl)=O Chemical compound COC(c(nc1)ccc1Nc1nccc2c1cccc2Cl)=O NINDRFYNLDAFAD-UHFFFAOYSA-N 0.000 description 1
- MKSIOSKQIQXIFT-UHFFFAOYSA-N COc1ccc(ccnc2Nc3ccc(C(NCc4cnccc4)=O)nc3)c2c1 Chemical compound COc1ccc(ccnc2Nc3ccc(C(NCc4cnccc4)=O)nc3)c2c1 MKSIOSKQIQXIFT-UHFFFAOYSA-N 0.000 description 1
- OOKBVDQQMQVJLI-UHFFFAOYSA-N C[n](c1ccc2)nnc1c2NS(c(cc1)ccc1Nc1nccc(cc2)c1cc2Cl)(=O)=O Chemical compound C[n](c1ccc2)nnc1c2NS(c(cc1)ccc1Nc1nccc(cc2)c1cc2Cl)(=O)=O OOKBVDQQMQVJLI-UHFFFAOYSA-N 0.000 description 1
- VCQCSCZRORPMQD-UHFFFAOYSA-N Cc1ccc(ccnc2Nc3ccc(C(NC4Cc5ccccc5CC4)=O)nc3)c2c1 Chemical compound Cc1ccc(ccnc2Nc3ccc(C(NC4Cc5ccccc5CC4)=O)nc3)c2c1 VCQCSCZRORPMQD-UHFFFAOYSA-N 0.000 description 1
- VURAWAWBESGKGW-UHFFFAOYSA-N N#Cc(cc1)cc2c1ccnc2Nc1ccc(C(NCc2cnccc2)=O)nc1 Chemical compound N#Cc(cc1)cc2c1ccnc2Nc1ccc(C(NCc2cnccc2)=O)nc1 VURAWAWBESGKGW-UHFFFAOYSA-N 0.000 description 1
- GDRQERMKGZAZHQ-UHFFFAOYSA-N O=C(c(nc1)ccc1Nc1nccc(cc2)c1cc2Cl)NCc(cc1)cc2c1OCC2 Chemical compound O=C(c(nc1)ccc1Nc1nccc(cc2)c1cc2Cl)NCc(cc1)cc2c1OCC2 GDRQERMKGZAZHQ-UHFFFAOYSA-N 0.000 description 1
- CCULROYFDNTNNM-UHFFFAOYSA-N O=C(c1nccc(Nc2nccc(cc3)c2cc3Cl)c1)NCC1Cc2ccccc2CC1 Chemical compound O=C(c1nccc(Nc2nccc(cc3)c2cc3Cl)c1)NCC1Cc2ccccc2CC1 CCULROYFDNTNNM-UHFFFAOYSA-N 0.000 description 1
- RMDOKPXVWTYSLF-UHFFFAOYSA-N O=S(c(cc1)ccc1Nc1c(cc(cc2)Cl)c2ccn1)(NCc1cc2n[s]nc2cc1)=O Chemical compound O=S(c(cc1)ccc1Nc1c(cc(cc2)Cl)c2ccn1)(NCc1cc2n[s]nc2cc1)=O RMDOKPXVWTYSLF-UHFFFAOYSA-N 0.000 description 1
- QJDZRKQNNYXLFM-UHFFFAOYSA-N O=S(c1cc(Nc(c2c3)nccc2ccc3Cl)ccc1)(NCC(c1cccnc1)N1CCCC1)=O Chemical compound O=S(c1cc(Nc(c2c3)nccc2ccc3Cl)ccc1)(NCC(c1cccnc1)N1CCCC1)=O QJDZRKQNNYXLFM-UHFFFAOYSA-N 0.000 description 1
- OJUIZBXDPRHMIF-UHFFFAOYSA-N O=S(c1cc(Nc2nccc(cc3)c2cc3Cl)ccc1)(NCC(c1ccccn1)N1CCOCC1)=O Chemical compound O=S(c1cc(Nc2nccc(cc3)c2cc3Cl)ccc1)(NCC(c1ccccn1)N1CCOCC1)=O OJUIZBXDPRHMIF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382660 | 2016-12-28 | ||
| EP16382660.5 | 2016-12-28 | ||
| PCT/IB2017/058438 WO2018122746A1 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019013593A2 true BR112019013593A2 (pt) | 2020-01-07 |
Family
ID=57777485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019013593-6A BR112019013593A2 (pt) | 2016-12-28 | 2017-12-27 | Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| CN122122139A (zh) * | 2023-11-02 | 2026-05-29 | Gt增益治疗股份有限公司 | 取代的吲哚基化合物、其组合物及其治疗用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| HRP20010795A2 (en) | 1999-04-28 | 2003-02-28 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
| WO2001058899A1 (en) | 2000-02-09 | 2001-08-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| EP1433776B1 (en) | 2001-09-07 | 2011-01-19 | Seikagaku Corporation | Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient |
| JP2006519258A (ja) | 2003-02-28 | 2006-08-24 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ii受容体拮抗薬 |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| WO2005070929A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Akt活性のある阻害剤 |
| CA2555914A1 (en) | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| WO2006058201A2 (en) * | 2004-11-23 | 2006-06-01 | Reddy Us Therapeutics, Inc. | Heterocyclic and bicyclic compounds, compositions and methods |
| BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| AU2006204750C1 (en) | 2005-01-14 | 2012-11-01 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| JP2010500330A (ja) | 2006-08-10 | 2010-01-07 | フエルレル インターナショナル,ソシエダッド アノニマ | Gabaa受容体に対して親和性を有する1h−キノリン−4−オン化合物、方法、使用及び組成物 |
| EP1903034A1 (en) | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosugar glycoconjugates |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2009049422A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease |
| CN102743385B (zh) * | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| ES2337435B8 (es) | 2008-10-22 | 2011-07-19 | Consejo Superior De Investigaciones Cientificas (Csic) (25%) | Compuestos potenciadores de la actividad de glicosidasas mutantes. |
| RU2505539C2 (ru) | 2008-12-23 | 2014-01-27 | Эбботт Лэборетриз | Антивирусные соединения |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| WO2011049737A1 (en) | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT2685986T (lt) | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| WO2013005168A2 (en) * | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| SG11201402765TA (en) * | 2011-12-30 | 2014-06-27 | Hanmi Pharm Ind Co Ltd | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| CA2883386A1 (en) * | 2012-09-14 | 2014-03-20 | Eternity Bioscience Inc. | Aminoisoquinoline derivatives as protein kinase inhibitors |
| BR122021012629B1 (pt) | 2013-02-01 | 2022-06-07 | Wellstat Therapeutics Corporation | Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos |
| EP3027590A1 (en) * | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
| AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| JP6239149B2 (ja) | 2014-04-25 | 2017-11-29 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンd1リガンドとしての使用 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016120808A1 (en) * | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
-
2017
- 2017-12-27 WO PCT/IB2017/058438 patent/WO2018122746A1/en not_active Ceased
- 2017-12-27 BR BR112019013593-6A patent/BR112019013593A2/pt not_active IP Right Cessation
- 2017-12-27 CN CN201780086786.5A patent/CN110494432B/zh not_active Expired - Fee Related
- 2017-12-27 ES ES17829043T patent/ES2862374T3/es active Active
- 2017-12-27 EP EP17829043.3A patent/EP3562821B9/en active Active
- 2017-12-27 CA CA3047700A patent/CA3047700A1/en active Pending
- 2017-12-27 AU AU2017388300A patent/AU2017388300B2/en not_active Ceased
- 2017-12-27 PL PL17829043T patent/PL3562821T3/pl unknown
- 2017-12-27 DK DK17829043.3T patent/DK3562821T3/da active
- 2017-12-27 JP JP2019535381A patent/JP7144863B2/ja active Active
- 2017-12-27 PT PT178290433T patent/PT3562821T/pt unknown
- 2017-12-27 US US16/473,966 patent/US11440898B2/en active Active
-
2019
- 2019-06-20 IL IL267553A patent/IL267553B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3562821T3 (da) | 2021-02-15 |
| AU2017388300A1 (en) | 2019-07-11 |
| AU2017388300B2 (en) | 2022-03-31 |
| CA3047700A1 (en) | 2018-07-05 |
| JP7144863B2 (ja) | 2022-09-30 |
| IL267553B (en) | 2021-10-31 |
| ES2862374T3 (es) | 2021-10-07 |
| CN110494432A (zh) | 2019-11-22 |
| IL267553A (en) | 2019-08-29 |
| EP3562821B9 (en) | 2021-05-26 |
| JP2020514284A (ja) | 2020-05-21 |
| PL3562821T3 (pl) | 2021-06-14 |
| WO2018122746A1 (en) | 2018-07-05 |
| US20200071294A1 (en) | 2020-03-05 |
| EP3562821A1 (en) | 2019-11-06 |
| CN110494432B (zh) | 2022-08-12 |
| EP3562821B1 (en) | 2020-12-02 |
| PT3562821T (pt) | 2021-03-03 |
| US11440898B2 (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110461846B (zh) | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 | |
| ES2761295T3 (es) | Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula | |
| ES2288694T3 (es) | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| BR112021002327A2 (pt) | derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer | |
| BR112013014242B1 (pt) | Composição farmacêutica e composto ou seu sal farmaceuticamente aceitável | |
| JP2013526511A (ja) | 医薬化合物 | |
| ES2953474T3 (es) | Nuevas quinazolinonas que inhiben la formación de oligómeros de tau y su modo de uso | |
| JP2016185947A (ja) | IRE−1αインヒビター | |
| BRPI0618752A2 (pt) | derivados de pirimidona bicìclica substituìda | |
| JP2022502497A (ja) | Hdac1、2の阻害剤 | |
| KR20090116716A (ko) | 칸나비노이드-cb1 길항작용과 아세틸콜린에스테라제 억제가 조합된 화합물 | |
| EP3562821B1 (en) | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | |
| EP4071140B1 (en) | Cftr regulators and methods of use thereof | |
| CN112074511A (zh) | 取代的苯并二唑及其在治疗中的用途 | |
| KR20160023854A (ko) | 프탈라진 유도체 | |
| KR20230104614A (ko) | 아세트아미도-페닐벤즈아미드 유도체 및 그의 사용 방법 | |
| HK40014193B (en) | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | |
| HK40014193A (en) | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | |
| EP4642455A1 (en) | Method of treating tauopathies | |
| KR102789906B9 (ko) | 신규 피리미딘 유도체 | |
| WO2023042177A1 (en) | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide | |
| EA052781B1 (ru) | Гетероарильные соединения и их терапевтическое применение при состояниях, связанных с изменением активности бета-глюкоцереброзидазы | |
| WO2025094117A1 (en) | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof | |
| HK40014578B (en) | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2861 DE 04-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |